In addition, in the TAC mouse model, treatment with the P2X7 receptor antagonist BBG reduced cardiac fibrosis and improved systolic function by inhibiting the expression of NLRP3 and IL-1β. This evidence concerns the gene NLRP3 and persistent truncus arteriosus.